APA (7th ed.) Citation

Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., . . . Ruella, M. (2024). T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature medicine, 30(4), 984-989. https://doi.org/10.1038/s41591-024-02826-w

Chicago Style (17th ed.) Citation

Ghilardi, Guido, et al. "T Cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T Cell Therapy." Nature Medicine 30, no. 4 (2024): 984-989. https://doi.org/10.1038/s41591-024-02826-w.

MLA (9th ed.) Citation

Ghilardi, Guido, et al. "T Cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T Cell Therapy." Nature Medicine, vol. 30, no. 4, 2024, pp. 984-989, https://doi.org/10.1038/s41591-024-02826-w.